Series B Biotech companies in London

Isomorphic Labs is here to advance human health by building on and beyond the Nobel-winning AlphaFold system. Our interdisciplinary team has developed a unified, state-of-the-art drug design engine that will transform how we design new drugs, and ultimately change the way medicine will help and heal people. Every day, and with each new breakthrough, we’re getting closer to achieving our ambitious mission to one day solve all disease

• Series B
• 402 employees
• Founded 2021

hVIVO plc (Ticker: HVO) is a science‐led early‐phase drug development company purpose‐built to meet the growing complexity of modern clinical research. The Company operates an integrated early‐phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‐ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.With industry‐leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‐growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‐built human challenge units in the world, complemented by additional early‐phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‐of‐concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.

• Series B
• 236 employees
• Founded 1989

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

• Series B
• 113 employees
• Founded 2019

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

• Series B
• 58 employees
• Founded 2020

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

• Series B
• 33 employees
• Founded 2016